USRE34656E - Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency - Google Patents
Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency Download PDFInfo
- Publication number
- USRE34656E USRE34656E US07/878,172 US87817292A USRE34656E US RE34656 E USRE34656 E US RE34656E US 87817292 A US87817292 A US 87817292A US RE34656 E USRE34656 E US RE34656E
- Authority
- US
- United States
- Prior art keywords
- tetracycline
- iaddend
- iadd
- accordance
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
Definitions
- tetracyclines such as the antibiotic tetracyclines, e.g. tetracycline
- antibiotic tetracyclines e.g. tetracycline
- compositions containing the same are disclosed therein as being useful in the treatment of periodontal diseases, corneal ulcers, rheumatoid arthritis and the like characterized by excessive collagen destruction.
- non-antibiotic or non-antibacterial tetracyclines also possess anti-collagenolytic properties and are useful as inhibitors of collagenase. Additionally, these non-antibiotic or non-antibacterial tetracyclines have also been found to be useful in the treatment of periodontal diseases, corneal ulcers, bone deficiency disorders due to excess collagenase production or excessivde collagen destruction, rheeumatoid arthristis and the like.
- a particularly useful non-antibiotic tetracycline in the practices of this invention is the tetracycline dedimethylaminotetracycline.
- Tetracyclines are useful as broad spectrum antibiotics because they have the ability to inhibit protein synthesis in a wide variety of bacteria.
- tetracyclines antibiotic tetracyclines and non-antibiotic tetracyclines, have th ability to inhibit collagen-destructive enzymes, such as collagenase, responsiple for the breakdown of connective tissue in a number of diseases, such as periodontal disease, corneal ulcers and rheumatoid arthritis.
- inhibitors of collagen-destructive enzymes are useful in the treatment of mammals, such as humans, to prevent the development of osteoporosis and/or to stimulate bone protein synthesis.
- an effective amount of a physiologically acceptable collagenase inhibitor is systemically administered to the mammal or human to bring about the stimulation of bone protein synthesis or to treat bone deficiency disease or osteoporosis.
- the amount of the inhibitor administered to the mammal or human can be at a therapeutic level, i.e. substantially the same dosage as would be employed in the treatment of barterial infections and the like, or at a reduced, subtherapeutic level, in the range about 5-60% of the therapeutic dosage.
- the amount administered in accordance with the practices of this invention would be effective to inhibit the collagen-destructive enzymes, such as collagenase, in the mammal, e.g. subject to which the inhibitor is administered.
- tetracyclines antibacterial and non-antibacterial tetracyclines, which are inhibitors of collagenase, enhance or stimulate bone protein synthesis and have been found to be useful in the treatment of osteoporosis in humans.
- tetracyclines stimulate and enhance bone protein synthesis, tetracyclines have been found to be useful in the treatment of osteoporosis.
- Tetracycline can inhibit tissue degradation by anticollagenase action and has reduced pathological bone resorption through this mechanism (Golub et al. 1983, 84).
- Bucco-lingual sections were prepared from bicuspid and cuspid teeth.
- a defined coronal buccal alveolar bone region was analyzed histologically and histometrically using step-serial sections.
- the marrow spaces appeared to be lined by new bone, as were the periodontal ligament surfaces of the alveolar bone.
- the increased bone density may have been due to inhibition of resorption without affecting the deposition phase of bone remodeling.
- Tetracyclines broadly, can be characterized as containing four fused carbcyclic groups. This arrangement appears to be characteristic of compounds which are collagenase inhibitors and which are also useful in the practices of this invention.
- Related compounds compounds which are related as analogs or homologs of tetracycline, are also useful as well as compounds which are characterized as having three fused carbocyclic groups.
- Suitable such compounds include 7-chlorotetracycline, 5-hydroxytetracycline, 6-demethyl-7-chlorotetracycline, 6-demethyl,-6-deoxy-5-hydroxy-6-methylenetetracycline, 6-alpha-benzylthiomethylenetetracycline, a nitrile analog of tetracycline, a mono-N-alkylated amide of tetracycline, 6-fluorodemethyltetracycline, 11-alpha-chlorotetracycline, 2-acetyl-8-hydroxy-1-tetracycline and 6-demethyl-6-deoxytetracycline.
- the compounds employed in the practices of this invention are employed in an effective amount for the treatment of osteoporosis, such as an amount effective to enhance the synthesis of bone protein and/or correct to treat any deficiency disease.
- the amount employed depends to some extent upon the body weight of the mammal or human being treated.
- the amount employed particularly in the case of compounds which are collagenase inhibitors and/or characterized as being a tetracycline, on a daily dosage, it is usually less than about 400 milligrams and usually below about 200 milligrams.
- a suitable daily dosage for a human would be in the range 10 milligrams to about 50 milligrams for the treatment of osteoporosis or other bone deficiency disease and for the enhancement of the synthesis of bone protein.
Abstract
Tetracyclines, antibacterial and non-antibacterial tetracyclines, have been found to be useful in the treatment of osteoporosis in humans by administering to the human suffering from osteoporosis an effective amount of a tetracycline to enhance bone protein synthesis. Tetracyclines which have been found to be effective in the treatment of osteoporosis in humans include minocycline, doxycycline and dedimethylaminotetracyline.
Description
This application is a continuation-in-part application of copending, coassigned patent application Ser. No. 699,048 filed Feb. 7, 1985, now U.S. Pat. No. 4,704,383 which in turn, is a continuation-in-part of copending, coassigned patent application Ser. No. 566,517 filed Dec. 29, 1983, now U.S. Pat. No. 4,666,897.
The disclosures of the above-identified applications are herein incorporated and made part of this disclosure.
In pending U.S. patent application Ser. No. 566,517, now U.S. Pat. No. 4,666,897, it is disclosed that tetracyclines, such as the antibiotic tetracyclines, e.g. tetracycline, are useful as anti-collagenolytic agents or as inhibitors of collagenase. These tetracyclines and compositions containing the same are disclosed therein as being useful in the treatment of periodontal diseases, corneal ulcers, rheumatoid arthritis and the like characterized by excessive collagen destruction.
In pending U.S. patent application Ser. No. 699,048, now U.S. Pat. No. 4,704,383, it is disclosed that the non-antibiotic or non-antibacterial tetracyclines also possess anti-collagenolytic properties and are useful as inhibitors of collagenase. Additionally, these non-antibiotic or non-antibacterial tetracyclines have also been found to be useful in the treatment of periodontal diseases, corneal ulcers, bone deficiency disorders due to excess collagenase production or excessivde collagen destruction, rheeumatoid arthristis and the like. A particularly useful non-antibiotic tetracycline in the practices of this invention is the tetracycline dedimethylaminotetracycline.
Tetracyclines are useful as broad spectrum antibiotics because they have the ability to inhibit protein synthesis in a wide variety of bacteria. As disclosed in the above-identified pending patent applications, it has also been discovered that tetracyclines, antibiotic tetracyclines and non-antibiotic tetracyclines, have th ability to inhibit collagen-destructive enzymes, such as collagenase, responsiple for the breakdown of connective tissue in a number of diseases, such as periodontal disease, corneal ulcers and rheumatoid arthritis.
It has been discovered that inhibitors of collagen-destructive enzymes, such as collagenase, are useful in the treatment of mammals, such as humans, to prevent the development of osteoporosis and/or to stimulate bone protein synthesis. In the practices of this invention an effective amount of a physiologically acceptable collagenase inhibitor is systemically administered to the mammal or human to bring about the stimulation of bone protein synthesis or to treat bone deficiency disease or osteoporosis. The amount of the inhibitor administered to the mammal or human can be at a therapeutic level, i.e. substantially the same dosage as would be employed in the treatment of barterial infections and the like, or at a reduced, subtherapeutic level, in the range about 5-60% of the therapeutic dosage. The amount administered in accordance with the practices of this invention would be effective to inhibit the collagen-destructive enzymes, such as collagenase, in the mammal, e.g. subject to which the inhibitor is administered.
More particularly, it has been discovered that tetracyclines, antibacterial and non-antibacterial tetracyclines, which are inhibitors of collagenase, enhance or stimulate bone protein synthesis and have been found to be useful in the treatment of osteoporosis in humans. In the light of the discovery of this invention that tetracyclines stimulate and enhance bone protein synthesis, tetracyclines have been found to be useful in the treatment of osteoporosis.
The following disclosures of examples are illustrative of the practices of this invention.
In this experiment 4 groups of adult male rats were set up, viz, a group of normal rats which served as controls, a group of rats that were rendered diabetic by streptozotocin administration and two additional groups of diabetic rats, one of which was administered by oral intubation 20 mg per day of a chemically modified non-antibiotic tetracycline (CMT), and the other of which was orally administered 5 mg per day of minocycline, a semi-synthetic commercially available antibiotic tetracycline. Each of the 4 groups of rats contained 4 rats each. Three weeks after beginning the experiment, but 2 hours before sacrifice, each rat was injected with 1 mCi of H3 -proline to radioactively label the newly synthesized protein in the skeletal and other tissues. After the rats were killed, the long bones were removed, cleaned free of soft tissue, the mid-shaft of the cleaned bone collected and hydrolyzed in 6N HCI (24 h, 105° C.), and an aliquot measured in a liquid scinitillation spectrometer after evaporating the acid. The data on bone protein synthesis is shown in Table 1.
TABLE I ______________________________________ The administration of minocycline or chemically-modified non-antibiotic tetracycline (CMT) to diabetic rats: effect on bone protein systhesis in vivo Bone Protein synthesis Experimental Group (DPM H.sup.3 -Pro/mg bone tissue) ______________________________________ Controls 886 ± 155 Diabetics (D) 588 ± 89 D + minocycline 852 ± 145 D + CMT 828 ± 248 ______________________________________
Inducing diabetes in the rat suppressed protein synthesis in the skeletal tissue; after months of this metabolic dysfunction in the bones, they developed physically and chemically-detectable bone-deficiency disease. When either of the two tetracyclines was orally administered to the diabetics, bone protein synthesis was increased to essentially normal values, and this metabolic alteration was associated with the prevention of the devleopment of osteoporosis.
In this experiment 3 groups of animals were established: a group of non-diabetic controls, a group of untreated diabetics, and a group of diabetic rats that were administered, by the oral route, 1.5 mg doxycycline, an antibiotic tetracycline, per day for the entire 31/2 month experimental period. After 3.5 months, the rats were killed, the bones (femur and tibia) were removed, defleshed, and radiographs taken. Physical and biochemical parameters were also measured. Other bones (mandible) were processed for light microscopy. Diabetes significantly reduced the dry weight, density, ash, matrix, calcium and hydroxyproline content of the skeletal tissue (the unchanged Ca/Hyp ratio indicated the bone was normally calcified even through osteopenic). Long-term doxycycline therapy retarded the loss of organic and inorganic bone constituents in the diabetics even though the severity of hyperglycemia was unaffected. Radiographic changes were consistent with the above findings. In short-term studies, treatment of diabetic rats with a different tetracycline (minocycline) showed a similar pattern of results. Tetracycline therapy in rats retarded osteoporotic changes in bone induced by diabetes.
It was observed that untreated diabetic rats developed bone deficiency disease, or osteoporosis, based on physical, radiologic, chemical and histologic assessments. However, the tetracycline, doxycycline, therapy prevented the development of diabetes-induced osteoporosis even though the drug had no effect on the severity of the diabetic state, presumably because the drug increased the depressed protein synthesis in the skeletal tissues.
TABLE II ______________________________________ Effects of CMT Administration (20 mg per day) on Urinary Calcium Excretion in Streptozotocum-Diabetic Rats Experimental Number of Rats μg Ca m Group per Group urine per 24 h* ______________________________________ Control 4 33 ± 5 Diabetes 4 691 ± 35 Diabetes + CMT 4 398 ± 33 ______________________________________ Each value represents the mean ± S.E.M. of 12 volumes: a 24 h determination was made for each rat (a = 4 per group), ondays 18, 19 and 20 after reducing diabetes
The results shown above in Table II summarizes the reduction in calcium excretion in the diabetic animals treated with CMT as compared with the untreated diabetic animals. Diabetes dramatically increases the urinary excretion of calcium compared with control values and an elevated urinary excretion of calcium is associated with the development of osteoporosis. Administration of CMT to the diabetic animals reduced the pathologically excessive excretion of calcium by 42%; this is biochemical evidence of the amelioration of the condition resulting from the administration of CMT.
Tetracycline can inhibit tissue degradation by anticollagenase action and has reduced pathological bone resorption through this mechanism (Golub et al. 1983, 84). A study was undertaken to evaluate whether tetracycline could have any discernible effect upon morphologic characteristics of bone undergoing nomral remodeling. Four squirrel monkeys received a daily dose of tetracycline at 100 mg/kg/day given by oral intubation in 3 equal doses. After 17 days of tetracycline administration the animals were sacrificed and the jaws processed for histologic sectioning. Bucco-lingual sections were prepared from bicuspid and cuspid teeth. A defined coronal buccal alveolar bone region was analyzed histologically and histometrically using step-serial sections. Corresponding regions were analyzed from bicuspids and cuspids from 4 animals which had not received tetracycline administration. Morphologic characteristics of the bone were analyzed using a Bioquant computerized digitization system, and comparisons made between the groups. Within the defined region, the total area of alveolar bone and the number of marrow spaces, did not differ between the two groups. However, the area of the narrow spaces was significantly less in tetracycline-receiving animals. The marrow spaces occupied 0.5±0.09(SE)% of the bone in tetracycline-receiving animals, in contrast to the 7.9±1.2(SE)% (t=3.49, p<0.01) present in control animals. In the tetracycline-receiving animals, the marrow spaces appeared to be lined by new bone, as were the periodontal ligament surfaces of the alveolar bone. The increased bone density may have been due to inhibition of resorption without affecting the deposition phase of bone remodeling.
Although in the practices of this invention many compounds, particularly physiologically acceptable collagenase inhibitors, are useful, it is preferred to employ a tetracycline antibiotic or non-antibiotic. Tetracyclines, broadly, can be characterized as containing four fused carbcyclic groups. This arrangement appears to be characteristic of compounds which are collagenase inhibitors and which are also useful in the practices of this invention. Related compounds, compounds which are related as analogs or homologs of tetracycline, are also useful as well as compounds which are characterized as having three fused carbocyclic groups. Suitable such compounds are disclosed herein and include 7-chlorotetracycline, 5-hydroxytetracycline, 6-demethyl-7-chlorotetracycline, 6-demethyl,-6-deoxy-5-hydroxy-6-methylenetetracycline, 6-alpha-benzylthiomethylenetetracycline, a nitrile analog of tetracycline, a mono-N-alkylated amide of tetracycline, 6-fluorodemethyltetracycline, 11-alpha-chlorotetracycline, 2-acetyl-8-hydroxy-1-tetracycline and 6-demethyl-6-deoxytetracycline.
As mentioned hereinabove, the compounds employed in the practices of this invention are employed in an effective amount for the treatment of osteoporosis, such as an amount effective to enhance the synthesis of bone protein and/or correct to treat any deficiency disease. The amount employed depends to some extent upon the body weight of the mammal or human being treated. With respect to humans, the amount employed, particularly in the case of compounds which are collagenase inhibitors and/or characterized as being a tetracycline, on a daily dosage, it is usually less than about 400 milligrams and usually below about 200 milligrams. A suitable daily dosage for a human would be in the range 10 milligrams to about 50 milligrams for the treatment of osteoporosis or other bone deficiency disease and for the enhancement of the synthesis of bone protein.
As will be apparent to those skilled in the art in the light of the foregoing disclosure, many alterations, substitutions and modifications are possible in the practices of this invention without departing from the spirit or scope thereof.
Claims (19)
1. .[.A.]. .Iadd.The .Iaddend.method of .[.enhancing bone protein synthesis in a human which comprises administering to the human an effective amount of a tetracycline.]..Iadd.claim 20 wherein said disease is osteoporosis .Iaddend..
2. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is an antibacterial tetracycline.
3. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is non-antibacterial tetracycline.
4. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is minocycline.
5. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is doxycycline.
6. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is 7-chlorotetracycline.
7. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is 5-hydroxytetracycline.
8. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is 6-demethyl-7-chlorotetracycline.
9. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is 6-demethyl-6-deoxy-5-bydroxy-6-methylenetetracycline.
10. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is dedimethylamimotetracycline.
11. A method in accoredance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is 6-alpha-benzylthiomethylenetetracycline.
12. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is a nitrile analog of tetracycline.
13. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is a mono-N-alkylated amide of tetracycline.
14. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is 6-fluorodemethyltetracycline.
15. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is 11-alpha-chlorotetracycline.
16. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is 2-acetyl-8-hydroxyl-1-tetracycline.
17. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is 6-demethyl-6-deoxytetracycline.
18. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is administered systemically.
19. A method in accordance with claim .[.1.]. .Iadd.20 .Iaddend.wherein said tetracycline is administered orally. .Iadd.20. A method of treating mammal with bone deficiency disease by enhancing bone protein synthesis in said mammal which comprises administering to the mammal an effective amount of a tetracycline. .Iaddend.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/878,172 USRE34656E (en) | 1983-12-29 | 1992-05-04 | Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/566,517 US4666897A (en) | 1983-12-29 | 1983-12-29 | Inhibition of mammalian collagenolytic enzymes by tetracyclines |
US06/699,048 US4704383A (en) | 1983-12-29 | 1985-02-07 | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
US06/946,726 US4925833A (en) | 1983-12-29 | 1986-12-29 | Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis |
US07/878,172 USRE34656E (en) | 1983-12-29 | 1992-05-04 | Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/699,048 Continuation-In-Part US4704383A (en) | 1983-12-29 | 1985-02-07 | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
US06/946,726 Reissue US4925833A (en) | 1983-12-29 | 1986-12-29 | Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE34656E true USRE34656E (en) | 1994-07-05 |
Family
ID=27415990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/878,172 Expired - Lifetime USRE34656E (en) | 1983-12-29 | 1992-05-04 | Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency |
Country Status (1)
Country | Link |
---|---|
US (1) | USRE34656E (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773430A (en) * | 1997-03-13 | 1998-06-30 | Research Foundation Of State University Of New York | Serine proteinase inhibitory activity by hydrophobic tetracycline |
WO2003005971A2 (en) | 2001-07-13 | 2003-01-23 | Paratek Pharmaceuticals, Inc. | Tetracycline compounds having target therapeutic activities |
US6610274B1 (en) | 2000-12-22 | 2003-08-26 | Wallace J. Gardner | Anti-inflammatory composition comprising tetracycline |
US20040029842A1 (en) * | 2001-12-18 | 2004-02-12 | Gardner Wallace J. | Triglyceride lowering, common cold and pneumonia prevention composition comprising tetracycline, and methods of treating or preventing diseases using same |
US20040228912A1 (en) * | 2003-04-07 | 2004-11-18 | Rong-Kun Chang | Once daily formulations of tetracyclines |
WO2005009943A2 (en) | 2003-07-09 | 2005-02-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
US20050079187A1 (en) * | 2003-10-14 | 2005-04-14 | Gardner Wallace J. | Composition, kit and method for reducing plaque formation, tooth decay and incidence of caries |
US20050186526A1 (en) * | 2002-11-01 | 2005-08-25 | Bas Medical, Inc. | Methods and systems for enabling and stabilizing tooth movement |
US20050267079A1 (en) * | 2001-10-05 | 2005-12-01 | Hlavka Joseph J | Tetracycline derivatives and methods of use thereof |
US20060194773A1 (en) * | 2001-07-13 | 2006-08-31 | Paratek Pharmaceuticals, Inc. | Tetracyline compounds having target therapeutic activities |
US20070093455A1 (en) * | 2005-07-21 | 2007-04-26 | Paul Abato | 10-substituted tetracyclines and methods of use thereof |
US20070269385A1 (en) * | 2006-05-18 | 2007-11-22 | Mercator Medsystems, Inc | Devices, methods, and systems for delivering therapeutic agents for the treatment of sinusitis, rhinitis, and other disorders |
US20080004596A1 (en) * | 2006-05-25 | 2008-01-03 | Palo Alto Institute | Delivery of agents by microneedle catheter |
US20080287401A1 (en) * | 2007-04-27 | 2008-11-20 | Sean Johnston | Methods for Synthesizing and Purifying Aminoalkyl Tetracycline Compounds |
US20080312193A1 (en) * | 2006-12-21 | 2008-12-18 | Haregewein Assefa | Substituted Tetracycline Compounds for Treatment of Inflammatory Skin Disorders |
US20090156842A1 (en) * | 2007-07-06 | 2009-06-18 | Farzaneh Seyedi | Methods for synthesizing substituted tetracycline compounds |
WO2009143509A1 (en) | 2008-05-23 | 2009-11-26 | Paratek Pharmaceuticals, Inc. | Salts and polymorphs of a tetracycline compound |
US20100204186A1 (en) * | 2004-01-15 | 2010-08-12 | Paratek Pharmaceuticals, Inc. | Aromatic a-ring derivatives of tetracycline compounds |
WO2010129057A2 (en) | 2009-05-08 | 2010-11-11 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
US20100305072A1 (en) * | 2006-12-21 | 2010-12-02 | Kim Oak K | Substituted Tetracycline Compounds |
EP2269991A2 (en) | 2004-10-25 | 2011-01-05 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
WO2011025982A2 (en) | 2009-08-28 | 2011-03-03 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
EP2292590A2 (en) | 2003-07-09 | 2011-03-09 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
EP2301534A1 (en) | 2002-03-08 | 2011-03-30 | Paratek Pharmaceuticals, Inc. | Amino-methyl substituted tetracycline compounds |
EP2301912A2 (en) | 2004-10-25 | 2011-03-30 | Paratek Pharmaceuticals, Inc. | 4-aminotetracyclines and methods of use thereof |
EP2311796A1 (en) | 2002-01-08 | 2011-04-20 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
EP2311440A1 (en) | 2001-04-05 | 2011-04-20 | Collagenex Pharmaceuticals, Inc. | Controlled delivery of tetracycline compounds and tetracycline derivatives |
EP2345637A2 (en) | 2002-07-12 | 2011-07-20 | Paratek Pharmaceuticals, Inc. | 3, 10, and 12a substituted tetracycline compounds |
WO2011123536A1 (en) | 2010-03-31 | 2011-10-06 | Tetraphase Pharmaceuticals, Inc. | Polycyclic tetracycline compounds |
EP2481723A2 (en) | 2002-03-21 | 2012-08-01 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2682387A2 (en) | 2008-08-08 | 2014-01-08 | Tetraphase Pharmaceuticals, Inc. | C7-fluoro substituted tetracycline compounds |
WO2018075767A1 (en) | 2016-10-19 | 2018-04-26 | Tetraphase Pharmaceuticals, Inc. | Crystalline forms of eravacycline |
EP3461809A1 (en) | 2012-08-31 | 2019-04-03 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB787882A (en) * | 1955-01-26 | 1957-12-18 | Lepetit Spa | Desdimethylaminotetracyclines and pharmaceutical preparations containing same |
US2895880A (en) * | 1955-05-13 | 1959-07-21 | Smith Kline French Lab | Sustained release pharmaceutical product |
GB925282A (en) * | 1960-05-04 | 1963-05-08 | Lepetit Spa | Fermentation process for the production of demethyltetracycline |
US3304227A (en) * | 1965-07-15 | 1967-02-14 | Loyal E Loveless | Antibiotic-containing animal feed |
US3636202A (en) * | 1968-02-12 | 1972-01-18 | Lewis A Klein | Treatment of rheumatoid arthritis and related diseases |
US3914299A (en) * | 1969-06-12 | 1975-10-21 | Research Corp | Tetracyclines |
US4248892A (en) * | 1978-06-09 | 1981-02-03 | Takeda Chemical Industries, Ltd. | Antifibrotic agent |
US4276284A (en) * | 1971-07-26 | 1981-06-30 | Brown Stuart I | Prevention of collagenase induced disease by treatment with collagenase inhibitors |
US4371465A (en) * | 1981-10-07 | 1983-02-01 | American Home Products Corporation | Mammalian collagenase inhibitors |
US4454110A (en) * | 1982-05-24 | 1984-06-12 | Forsyth Dental Infirmary For Children | Self-gelling liquid composition for topical application in the oral cavity |
US4457936A (en) * | 1980-01-29 | 1984-07-03 | Hoechst Aktiengesellschaft | Use of hydroxyphenyl-thiazole-, -thiazoline- and -thiazolidine-carboxylic acids, for influencing the collagen metabolism |
US4666897A (en) * | 1983-12-29 | 1987-05-19 | Research Foundation Of State University | Inhibition of mammalian collagenolytic enzymes by tetracyclines |
US4704383A (en) * | 1983-12-29 | 1987-11-03 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
US4925833A (en) * | 1983-12-29 | 1990-05-15 | The Research Foundation Of State University Of New York | Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis |
US4935412A (en) * | 1983-12-29 | 1990-06-19 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
-
1992
- 1992-05-04 US US07/878,172 patent/USRE34656E/en not_active Expired - Lifetime
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB787882A (en) * | 1955-01-26 | 1957-12-18 | Lepetit Spa | Desdimethylaminotetracyclines and pharmaceutical preparations containing same |
US2895880A (en) * | 1955-05-13 | 1959-07-21 | Smith Kline French Lab | Sustained release pharmaceutical product |
GB925282A (en) * | 1960-05-04 | 1963-05-08 | Lepetit Spa | Fermentation process for the production of demethyltetracycline |
US3304227A (en) * | 1965-07-15 | 1967-02-14 | Loyal E Loveless | Antibiotic-containing animal feed |
US3636202A (en) * | 1968-02-12 | 1972-01-18 | Lewis A Klein | Treatment of rheumatoid arthritis and related diseases |
US3914299A (en) * | 1969-06-12 | 1975-10-21 | Research Corp | Tetracyclines |
US4276284A (en) * | 1971-07-26 | 1981-06-30 | Brown Stuart I | Prevention of collagenase induced disease by treatment with collagenase inhibitors |
US4248892A (en) * | 1978-06-09 | 1981-02-03 | Takeda Chemical Industries, Ltd. | Antifibrotic agent |
US4457936A (en) * | 1980-01-29 | 1984-07-03 | Hoechst Aktiengesellschaft | Use of hydroxyphenyl-thiazole-, -thiazoline- and -thiazolidine-carboxylic acids, for influencing the collagen metabolism |
US4371465A (en) * | 1981-10-07 | 1983-02-01 | American Home Products Corporation | Mammalian collagenase inhibitors |
US4454110A (en) * | 1982-05-24 | 1984-06-12 | Forsyth Dental Infirmary For Children | Self-gelling liquid composition for topical application in the oral cavity |
US4666897A (en) * | 1983-12-29 | 1987-05-19 | Research Foundation Of State University | Inhibition of mammalian collagenolytic enzymes by tetracyclines |
US4704383A (en) * | 1983-12-29 | 1987-11-03 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
US4925833A (en) * | 1983-12-29 | 1990-05-15 | The Research Foundation Of State University Of New York | Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis |
US4935412A (en) * | 1983-12-29 | 1990-06-19 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
US4935411A (en) * | 1983-12-29 | 1990-06-19 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
Non-Patent Citations (62)
Title |
---|
"Anti-Plaque Agents", Pharmacy Times, 97 (Jul. 1985). |
"British Bio-Technology Group's Collagenase Inhibitor Adjunctive", F-D-C Reports, Inc., 13 (1983). |
"Periodontal Disease Research, Guide to Dental Health", Journal of the American Dental Association, 70-74 (1985). |
"Zyderm Collagen Treatments", Collagen Corporation, Advertisement, (Dec. 1981). |
Addy, et al., "Comparison of the Immediate Effects on the Subgingival Microflora of Acrylic Strips Containing 40% Chlorhexdine, Metronidazole or Tetracycline", Journal of Clinical Periodontology, 11:379-386, (1984). |
Addy, et al., "The Development and in Vitro Evaluation of Acrylic Strips and Dialysis Tubing for Local Drug Delivery", J. Periodonal, 693-699, (Nov. 1982). |
Addy, et al., Comparison of the Immediate Effects on the Subgingival Microflora of Acrylic Strips Containing 40% Chlorhexdine, Metronidazole or Tetracycline , Journal of Clinical Periodontology , 11:379 386, (1984). * |
Addy, et al., The Development and in Vitro Evaluation of Acrylic Strips and Dialysis Tubing for Local Drug Delivery , J. Periodonal , 693 699, (Nov. 1982). * |
ALZA/P&G Periodontal Disease Partnership:Actisite, F D C Reports , Inc., 8 9 (1990). * |
ALZA/P&G Periodontal Disease Partnership:Actisite, F-D-C Reports, Inc., 8-9 (1990). |
Anti Plaque Agents , Pharmacy Times , 97 (Jul. 1985). * |
Berman, M. B., "Collagenase and Corneal Ulceration", 8:141-174, (1980). |
Berman, M. B., Collagenase and Corneal Ulceration , 8:141 174, (1980). * |
Bitha, et al., Chemical Abstracts , 72:43253P, (1970). * |
Bitha, et al., Chemical Abstracts, 72:43253P, (1970). |
Brandt, et al., Chemical Abstracts , 92:163746m, (1979). * |
Brandt, et al., Chemical Abstracts, 92:163746m, (1979). |
British Bio Technology Group s Collagenase Inhibitor Adjunctive , F D C Reports , Inc., 13 (1983). * |
Brown et al., "Rheumatoid Artritis in the Gorilla:A Study of Mycoplasma-Host Interaction in Pathogenesis and Treatment", Comarative Pathology of Zoo Animals, 259-266, (1980). |
Brown et al., Rheumatoid Artritis in the Gorilla:A Study of Mycoplasma Host Interaction in Pathogenesis and Treatment , Comarative Pathology of Zoo Animals , 259 266, (1980). * |
Dreisbach, et al., "Induction of Collagenase Production in Vibrio B--30", J. Bacteriology, vol. 135, No. 2, pp. 521-527, (1978). |
Dreisbach, et al., Induction of Collagenase Production in Vibrio B 30 , J. Bacteriology , vol. 135, No. 2, pp. 521 527, (1978). * |
Engesaeter, et al., Chemical Abstracts , 93:142977t, (1980). * |
Engesaeter, et al., Chemical Abstracts, 93:142977t, (1980). |
Glantz, et al., Chemical Abstracts , 91:20178w, (1979). * |
Glantz, et al., Chemical Abstracts, 91:20178w, (1979). |
Golub, et al., "Minocycline Reduces Gingival Collagenolytic Activity During Diabetes", Journal of Periodontal Research, 18: 516-526 (1983). |
Golub, et al., "Minocycline Therapy Inhibits the Abnormal Gingival Collagenolytic Activity During Experimental Diabetes", Journal of Dental Research, 62:290, Abstract 1085, (1983). |
Golub, et al., "Minocycline Therapy Reduces Gingival Collagenolytic Enzyme Activity During Diabetes: A Proposed New Mechanism of Action, J. Of Periodontal Research", 18: 516-526, Abstract, (1983). |
Golub, et al., Chemical Abstracts , 100:96203a, (1984). * |
Golub, et al., Chemical Abstracts, 100:96203a, (1984). |
Golub, et al., Minocycline Reduces Gingival Collagenolytic Activity During Diabetes , Journal of Periodontal Research , 18: 516 526 (1983). * |
Golub, et al., Minocycline Therapy Inhibits the Abnormal Gingival Collagenolytic Activity During Experimental Diabetes , Journal of Dental Research , 62:290, Abstract 1085, (1983). * |
Golub, et al., Minocycline Therapy Reduces Gingival Collagenolytic Enzyme Activity During Diabetes: A Proposed New Mechanism of Action, J. Of Periodontal Research , 18: 516 526, Abstract, (1983). * |
Gomes, et al., "Tetracyclines Inhibit Parathyroid Hormone-Induced Bone Resorption in Organ Culture", School of Dental Medicine Study, SUNY, (Mar. 19, 1984). |
Gomes, et al., Tetracyclines Inhibit Parathyroid Hormone Induced Bone Resorption in Organ Culture , School of Dental Medicine Study, SUNY, (Mar. 19, 1984). * |
Goodman and Gilman, The Pharmacological Basis of Therapeutics , 6th edition, p. 961 2, (1980). * |
Goodman and Gilman, The Pharmacological Basis of Therapeutics, 6th edition, p. 961-2, (1980). |
Goodson, et al., "Monolithic Tetracycline-containing Fibers for Controlled Delivery to Periodontal Pockets", J. Periodontol. 54 575-579 (Jan. 1983). |
Goodson, et al., Monolithic Tetracycline containing Fibers for Controlled Delivery to Periodontal Pockets , J. Periodontol. 54 575 579 (Jan. 1983). * |
Katz, S. E., "Is Today's Meat Fit to Eat?", Chemical and Engineering News, 80-81 (Mar. 11, 1985). |
Katz, S. E., Is Today s Meat Fit to Eat , Chemical and Engineering News , 80 81 (Mar. 11, 1985). * |
Muxfeldt, Chemical Abstracts , 76:140344j, (1972). * |
Muxfeldt, Chemical Abstracts, 76:140344j, (1972). |
Myl nikova, Chemical Abstracts , 86:66138h, (1976). * |
Myl'nikova, Chemical Abstracts, 86:66138h, (1976). |
O Donovan, J. P., A Chick Screen to Evaluate Chemical Compounds from Janssen Pharmaceutical for Growth Promotion , Chick Growth Promotion Screen Report (1987). * |
O'Donovan, J. P., "A Chick Screen to Evaluate Chemical Compounds from Janssen Pharmaceutical for Growth Promotion", Chick Growth Promotion Screen Report (1987). |
Periodontal Disease Research, Guide to Dental Health , Journal of the American Dental Association , 70 74 (1985). * |
Perry, et al., "Systemic Tetracycline in the Treatment of Non-Infected Corneal Ulcers and Persistent Epithelial Defects", J. Period Res. 83:20, 185-195 (Abstract and Artide) (1984). |
Perry, et al., Systemic Tetracycline in the Treatment of Non Infected Corneal Ulcers and Persistent Epithelial Defects , J. Period Res. 83:20, 185 195 (Abstract and Artide) (1984). * |
Plakunov, Chemical Abstracts , 80:104410b, (1973). * |
Plakunov, Chemical Abstracts, 80:104410b, (1973). |
Sheridan, P., "Tetracyclines Block Collagenase Activity", JAMA, 252, 1989-1990 (Oct. 19, 1984). |
Sheridan, P., Tetracyclines Block Collagenase Activity , JAMA , 252, 1989 1990 (Oct. 19, 1984). * |
Smirnov, I. V., Chemical Abstracts , 76:30596, (1969). * |
Smirnov, I. V., Chemical Abstracts, 76:30596, (1969). |
Valcavi, et al., Chemical Abstracts , 95:6899h, (1981). * |
Valcavi, et al., Chemical Abstracts, 95:6899h, (1981). |
Williams et al., "Tetracycline Treatment of Periodontal Disease in the Beagle Dog:", Journal of Periodontal Research, 16:555-674, (1981). |
Williams et al., Tetracycline Treatment of Periodontal Disease in the Beagle Dog: , Journal of Periodontal Research , 16:555 674, (1981). * |
Zyderm Collagen Treatments , Collagen Corporation, Advertisement, (Dec. 1981). * |
Cited By (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773430A (en) * | 1997-03-13 | 1998-06-30 | Research Foundation Of State University Of New York | Serine proteinase inhibitory activity by hydrophobic tetracycline |
US6610274B1 (en) | 2000-12-22 | 2003-08-26 | Wallace J. Gardner | Anti-inflammatory composition comprising tetracycline |
EP2311440A1 (en) | 2001-04-05 | 2011-04-20 | Collagenex Pharmaceuticals, Inc. | Controlled delivery of tetracycline compounds and tetracycline derivatives |
EP2332546A1 (en) | 2001-07-13 | 2011-06-15 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of stroke |
EP2301915A1 (en) | 2001-07-13 | 2011-03-30 | Paratek Pharmaceuticals, Inc. | 7-(diethylamino)methyl substituted tetracycline having target therapeutic activities |
EP2329826A1 (en) | 2001-07-13 | 2011-06-08 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of multiple sclerosis |
WO2003005971A2 (en) | 2001-07-13 | 2003-01-23 | Paratek Pharmaceuticals, Inc. | Tetracycline compounds having target therapeutic activities |
EP2332549A1 (en) | 2001-07-13 | 2011-06-15 | Paratek Pharmaceuticals, Inc. | Novel tetracyclines and their use in medicine |
EP2329828A1 (en) | 2001-07-13 | 2011-06-08 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of ischaemia |
US20060194773A1 (en) * | 2001-07-13 | 2006-08-31 | Paratek Pharmaceuticals, Inc. | Tetracyline compounds having target therapeutic activities |
EP2332547A1 (en) | 2001-07-13 | 2011-06-15 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of inflammatory bowel disease |
EP2332550A1 (en) | 2001-07-13 | 2011-06-15 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of neurodegenerative diseases |
EP2327409A1 (en) | 2001-07-13 | 2011-06-01 | Paratek Pharmaceuticals, Inc. | Tetracycline compound having target therapeutic activities |
EP2332548A1 (en) | 2001-07-13 | 2011-06-15 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of stroke |
EP2301550A1 (en) | 2001-07-13 | 2011-03-30 | Paratek Pharmaceuticals, Inc. | Tetracycline compounds having target therapeutic activities |
US20050267079A1 (en) * | 2001-10-05 | 2005-12-01 | Hlavka Joseph J | Tetracycline derivatives and methods of use thereof |
US20070149488A1 (en) * | 2001-10-05 | 2007-06-28 | Hlavka Joseph J | Tetracycline Derivatives and Methods of Use Thereof |
US7214669B2 (en) | 2001-10-05 | 2007-05-08 | Tetragenex Pharmaceuticals, Inc. | Tetracycline derivatives and methods of use thereof |
US20070142338A1 (en) * | 2001-10-05 | 2007-06-21 | Hlavka Joseph J | Tetracycline Derivatives and Methods of Use Thereof |
US20040029842A1 (en) * | 2001-12-18 | 2004-02-12 | Gardner Wallace J. | Triglyceride lowering, common cold and pneumonia prevention composition comprising tetracycline, and methods of treating or preventing diseases using same |
EP2311797A1 (en) | 2002-01-08 | 2011-04-20 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
EP2311796A1 (en) | 2002-01-08 | 2011-04-20 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
EP2311799A1 (en) | 2002-01-08 | 2011-04-20 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
EP2322501A1 (en) | 2002-01-08 | 2011-05-18 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
EP2311798A1 (en) | 2002-01-08 | 2011-04-20 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
EP2995610A1 (en) | 2002-01-08 | 2016-03-16 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
EP2316450A1 (en) | 2002-03-08 | 2011-05-04 | Paratek Pharmaceuticals, Inc. | Amino-methyl substituted tetracycline compounds |
EP2301534A1 (en) | 2002-03-08 | 2011-03-30 | Paratek Pharmaceuticals, Inc. | Amino-methyl substituted tetracycline compounds |
EP2311451A1 (en) | 2002-03-08 | 2011-04-20 | Paratek Pharmaceuticals, Inc. | Amino-methyl substituted tetracycline compounds |
EP2481723A2 (en) | 2002-03-21 | 2012-08-01 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2345637A2 (en) | 2002-07-12 | 2011-07-20 | Paratek Pharmaceuticals, Inc. | 3, 10, and 12a substituted tetracycline compounds |
US20050186526A1 (en) * | 2002-11-01 | 2005-08-25 | Bas Medical, Inc. | Methods and systems for enabling and stabilizing tooth movement |
US7749532B2 (en) | 2003-04-07 | 2010-07-06 | Supernus Pharmaceuticals, Inc. | Once daily formulations of tetracyclines |
US8709478B2 (en) | 2003-04-07 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Once daily formulations of tetracyclines |
US20040228912A1 (en) * | 2003-04-07 | 2004-11-18 | Rong-Kun Chang | Once daily formulations of tetracyclines |
US8470364B2 (en) | 2003-04-07 | 2013-06-25 | Supernus Pharmaceuticals, Inc. | Once daily formulations of tetracyclines |
US8394406B2 (en) | 2003-04-07 | 2013-03-12 | Supernus Pharmaceuticals, Inc. | Once daily formulations of tetracyclines |
US8394405B2 (en) | 2003-04-07 | 2013-03-12 | Supernus Pharmaceuticals, Inc. | Once daily formulations of tetracyclines |
US8206740B2 (en) | 2003-04-07 | 2012-06-26 | Supernus Pharmaceuticals, Inc. | Once daily formulations of tetracyclines |
US20090011006A1 (en) * | 2003-04-07 | 2009-01-08 | Supernus Pharmaceuticals, Inc. | Once daily formulations of tetracyclines |
EP2319829A1 (en) | 2003-07-09 | 2011-05-11 | Paratek Pharmaceuticals, Inc. | 9-substituted tetracycline compounds |
EP2319828A2 (en) | 2003-07-09 | 2011-05-11 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2292590A2 (en) | 2003-07-09 | 2011-03-09 | Paratek Pharmaceuticals, Inc. | Prodrugs of 9-aminomethyl tetracycline compounds |
EP2295404A2 (en) | 2003-07-09 | 2011-03-16 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2298323A2 (en) | 2003-07-09 | 2011-03-23 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2298322A2 (en) | 2003-07-09 | 2011-03-23 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
WO2005009943A2 (en) | 2003-07-09 | 2005-02-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
US20050079187A1 (en) * | 2003-10-14 | 2005-04-14 | Gardner Wallace J. | Composition, kit and method for reducing plaque formation, tooth decay and incidence of caries |
EP2332904A2 (en) | 2004-01-15 | 2011-06-15 | Paratek Pharmaceuticals, Inc. | Derivatives of tetracycline compounds |
US7786099B2 (en) | 2004-01-15 | 2010-08-31 | Paratek Pharmaceuticals, Inc. | Aromatic a-ring derivatives of tetracycline compounds |
US20100204186A1 (en) * | 2004-01-15 | 2010-08-12 | Paratek Pharmaceuticals, Inc. | Aromatic a-ring derivatives of tetracycline compounds |
EP2301912A2 (en) | 2004-10-25 | 2011-03-30 | Paratek Pharmaceuticals, Inc. | 4-aminotetracyclines and methods of use thereof |
EP2284152A2 (en) | 2004-10-25 | 2011-02-16 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2305637A2 (en) | 2004-10-25 | 2011-04-06 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2295419A2 (en) | 2004-10-25 | 2011-03-16 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2949644A2 (en) | 2004-10-25 | 2015-12-02 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2287140A2 (en) | 2004-10-25 | 2011-02-23 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2287148A2 (en) | 2004-10-25 | 2011-02-23 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2287150A2 (en) | 2004-10-25 | 2011-02-23 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2284156A2 (en) | 2004-10-25 | 2011-02-16 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2284155A2 (en) | 2004-10-25 | 2011-02-16 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2284164A2 (en) | 2004-10-25 | 2011-02-16 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2301916A2 (en) | 2004-10-25 | 2011-03-30 | Paratek Pharmaceuticals, Inc. | 4-aminotetracyclines and methods of use thereof |
EP2284153A2 (en) | 2004-10-25 | 2011-02-16 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2284150A2 (en) | 2004-10-25 | 2011-02-16 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2284151A2 (en) | 2004-10-25 | 2011-02-16 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2269985A2 (en) | 2004-10-25 | 2011-01-05 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2269978A2 (en) | 2004-10-25 | 2011-01-05 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
EP2269991A2 (en) | 2004-10-25 | 2011-01-05 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
US20070093455A1 (en) * | 2005-07-21 | 2007-04-26 | Paul Abato | 10-substituted tetracyclines and methods of use thereof |
US20070269385A1 (en) * | 2006-05-18 | 2007-11-22 | Mercator Medsystems, Inc | Devices, methods, and systems for delivering therapeutic agents for the treatment of sinusitis, rhinitis, and other disorders |
US20080004596A1 (en) * | 2006-05-25 | 2008-01-03 | Palo Alto Institute | Delivery of agents by microneedle catheter |
EP2452935A2 (en) | 2006-12-21 | 2012-05-16 | Paratek Pharmaceuticals, Inc. | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections |
EP3045449A1 (en) | 2006-12-21 | 2016-07-20 | Paratek Pharmaceuticals, Inc. | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections |
EP3812372A2 (en) | 2006-12-21 | 2021-04-28 | Paratek Pharmaceuticals, Inc. | 7-heterocyclyl substituted sancycline derivatives for treating bacterial, viral and parasitic infections (e.g. malaria) or inflammatory diseases |
EP2450347A1 (en) | 2006-12-21 | 2012-05-09 | Paratek Pharmaceuticals, Inc. | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections |
US9481639B2 (en) | 2006-12-21 | 2016-11-01 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
EP2455367A1 (en) | 2006-12-21 | 2012-05-23 | Paratek Pharmaceuticals, Inc. | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections |
US20100305072A1 (en) * | 2006-12-21 | 2010-12-02 | Kim Oak K | Substituted Tetracycline Compounds |
US9012433B2 (en) | 2006-12-21 | 2015-04-21 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
US8318706B2 (en) | 2006-12-21 | 2012-11-27 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
US8513223B2 (en) | 2006-12-21 | 2013-08-20 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
US20080312193A1 (en) * | 2006-12-21 | 2008-12-18 | Haregewein Assefa | Substituted Tetracycline Compounds for Treatment of Inflammatory Skin Disorders |
US9434680B2 (en) | 2007-04-27 | 2016-09-06 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing and purifying aminoalkyl tetracycline compounds |
EP2213655A1 (en) | 2007-04-27 | 2010-08-04 | Paratek Pharmaceuticals, Inc. | Methods For Purifying Aminoalkyl Tetracycline Compounds |
US8946196B2 (en) | 2007-04-27 | 2015-02-03 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing and purifying aminoalkyl tetracycline compounds |
US20080287401A1 (en) * | 2007-04-27 | 2008-11-20 | Sean Johnston | Methods for Synthesizing and Purifying Aminoalkyl Tetracycline Compounds |
US20100113401A1 (en) * | 2007-04-27 | 2010-05-06 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing and purifying aminoalkyl tetracycline compounds |
US9522872B2 (en) | 2007-07-06 | 2016-12-20 | Paratek Pharmaceuticals, Inc. | Methods for synthesizing substituted tetracycline compounds |
US20090156842A1 (en) * | 2007-07-06 | 2009-06-18 | Farzaneh Seyedi | Methods for synthesizing substituted tetracycline compounds |
US8383610B2 (en) | 2008-05-23 | 2013-02-26 | Paratek Pharmaceuticals, Inc. | Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
EP3827817A1 (en) | 2008-05-23 | 2021-06-02 | Paratek Pharmaceuticals, Inc. | Salts and polymorphs of a tetracycline compound |
EP2807926A1 (en) | 2008-05-23 | 2014-12-03 | Paratek Pharmaceuticals, Inc. | Salts and plymorphs of a tetracycline compound |
WO2009143509A1 (en) | 2008-05-23 | 2009-11-26 | Paratek Pharmaceuticals, Inc. | Salts and polymorphs of a tetracycline compound |
US20100113399A1 (en) * | 2008-05-23 | 2010-05-06 | Paratek Pharmaceuticals, Inc. | Salts and Polymorphs of a Tetracycline Compound |
EP3000805A1 (en) | 2008-08-08 | 2016-03-30 | Tetraphase Pharmaceuticals, Inc. | C7-fluoro substituted tetracycline compounds |
EP2682387A2 (en) | 2008-08-08 | 2014-01-08 | Tetraphase Pharmaceuticals, Inc. | C7-fluoro substituted tetracycline compounds |
WO2010129057A2 (en) | 2009-05-08 | 2010-11-11 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
WO2011025982A2 (en) | 2009-08-28 | 2011-03-03 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
EP3275861A1 (en) | 2009-08-28 | 2018-01-31 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
WO2011123536A1 (en) | 2010-03-31 | 2011-10-06 | Tetraphase Pharmaceuticals, Inc. | Polycyclic tetracycline compounds |
EP3461809A1 (en) | 2012-08-31 | 2019-04-03 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
WO2018075767A1 (en) | 2016-10-19 | 2018-04-26 | Tetraphase Pharmaceuticals, Inc. | Crystalline forms of eravacycline |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4925833A (en) | Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis | |
USRE34656E (en) | Use of tetracycline to enhance bone protein synthesis and/or treatment of bone deficiency | |
EP0137668B1 (en) | Ibuprofen, flurbiprofen and their therapeutic use | |
Xu et al. | Simvastatin prevents alveolar bone loss in an experimental rat model of periodontitis after ovariectomy | |
Marks Jr et al. | Local infusion of prostaglandin E1 stimulates mandibular bone formation in vivo | |
RU95102778A (en) | Use of 2-phenyl-3-aroylbenzothiophenes for osseous tissue loss inhibition and serum cholesterol level decrease, pharmaceutical preparation containing 2-phenyl-3-aroylbenzothiophene | |
US5902110A (en) | Bone regeneration | |
AU2267395A (en) | Benzofuran derivatives useful as inhibitors of bone resorption | |
JPH06192103A (en) | Nonsteroid anti-inflammation agent and composition containing actually non-antibiotic tetracycline | |
RU2008103617A (en) | BISPHOSPHONIC ACIDS INTENDED FOR TREATMENT AND PREVENTION OF OSTEOPOROSIS | |
CA2151240A1 (en) | Biophosphonate/estrogen therapy for treating and preventing bone loss | |
WO1987004618A1 (en) | Treatment of bone loss | |
DE69330498T2 (en) | PHOSPHONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | |
BR0010257A (en) | Compound, process for the preparation of a compound, pharmaceutical formulation, use of a compound, method for treatment or prophylaxis of conditions associated with the inhibition of carboxypeptidase u, kits of parts, and method of treating a patient suffering from or susceptible to a condition where inhibition of carboxypeptidase and a different antithrombotic mechanism are needed or desired | |
KR970702291A (en) | Anequilin double bond isomer from the acid isomerization of equilin | |
KR970061244A (en) | Pharmaceutical composition for treating dementia | |
BRPI0418973A (en) | risedronate compositions and their methods of use | |
Zhang et al. | Effect of doxycycline doped bone substitute on vertical bone augmentation on rat calvaria | |
HK1087039A1 (en) | Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass | |
KR970061249A (en) | Compositions for Treating or Preventing Osteoporosis | |
DE69420776T2 (en) | Compositions containing idebenone for the treatment of M. Alzheimer's | |
BR0010256A (en) | Compound, process for the preparation of a compound, pharmaceutical formulation, use of a compound, method of treatment or prophylaxis of conditions associated with the inhibition of carboxypeptidase u, kit of parts, and method of treatment of a patient suffering from or susceptible to a condition where inhibition of carboxypeptidase and a different antithrombotic mechanism are required | |
BR9502072A (en) | Compound method for the treatment of a medical condition and pharmaceutical composition | |
US7955623B2 (en) | Pharmaceutical preparations for treating inflammatory diseases | |
WO2018095264A1 (en) | Notch signalling pathway regulator for regulating bone formation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
RR | Request for reexamination filed |
Effective date: 20030819 |
|
B1 | Reexamination certificate first reexamination |
Free format text: CLAIMS 9 AND 20 ARE DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 1-8 AND 10-19, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE. NEW CLAIMS 21-28 ARE ADDED AND DETERMINED TO BE PATENTABLE. |